Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
Clin. transl. oncol. (Print)
; 19(2): 219-226, feb. 2017. tab, graf
Article
in En
| IBECS
| ID: ibc-159455
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Background/Aim. First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab. Patients and methods. This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months. Results. Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies. Conclusion. Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors (AU)
RESUMEN
No disponible
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Maintenance Chemotherapy
/
Bevacizumab
/
Survivorship
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2017
Document type:
Article